VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

222

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Psoriasis

Interventions

DRUG: VTX958 Dose A
DRUG: VTX958 Dose B
DRUG: VTX958 Dose C
DRUG: VTX958 Dose D
DRUG: Placebo

Sponsor

Ventyx Biosciences, Inc